详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Long-term outcomes of treatments for central precocious puberty or early and fast puberty in Chinese girls.

文献详情

资源类型：

作者：

机构： [1]Children’s Hospital of Zhejiang University School of Medicine 310051, Hangzhou, China [2]Fuzhou Children’s Hospital of Fujian, Fujian Medical University Teaching Hospital, Fuzhou, China [3]Ruijin Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, China [4]The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China [5]Children’s Hospital of Soochow University, Suzhou, China [6]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [7]Children’s Hospital of Jiangxi Province, Nancang, China [8]Children's Hospital of Chongqing Medical University, Chongqing, China [9]Shenzhen Children’s Hospital, Shenzhen, China [10]Lishui City People’s Hospital, Lishui, China [11]Wuhan Children's Hospital, Wuhan, China [12]Shaoxing Women and Children’s Hospital, Shaoxing, China [13]Beijing Children’s Hospital, Capital Medical University, Beijing, China

出处：

DOI：

ISSN：

摘要：

Gonadotropin-releasing hormone analogues (GnRHa) and recombinant human growth hormone (rhGH) have been widely used to treat idiopathic central precocious puberty (CPP) or early and fast puberty (EFP). However, large-scale studies to evaluate the treatment effects on final adult height (FAH) are still lacking. To assess the effects of long-term treatment for CPP/EFP on FAH and its main influencing factors. Retrospective, multi-center observational study from 1998-2017. Four hundred forty-eight Chinese girls with CPP/EFP received GnRHa and rhGH treatment (n=118), GnRHa alone (n=276), or no treatment (n=54). FAH, target height (Tht), and predictive adult height (PAH). The height gain (FAH-PAH) was significantly different among the GnRHa and rhGH treatment, GnRHa alone, and no treatment groups (p<0.05; 9.51±0.53, 8.07±0.37, and 6.44±0.91 cm, respectively). The genetic height gain (FAH-Tht) was 4.0±0.5 cm for the GnRHa+rhGH group and 2.0±0.27 cm for the GnRHa group, while the control group reached their Tht. In addition, five critical parameters derived from PAH, bone age, and Tht, showed excellent performance in predicting which patients could gain ≥5 cm (FAH-PAH), and this was further validated using an independent study. The overall beneficial effect of GnRHa+rhGH or GnRHa on FAH was significant. The control group also reached their genetic target height. Clinicians are recommended to consider both the potential gains in height and the cost of medication. © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 2 区

医学

小类 | 2 区内分泌学与代谢

最新[2023]版：

大类 | 2 区

医学

小类 | 2 区内分泌学与代谢

第一作者：

第一作者机构： [1]Children’s Hospital of Zhejiang University School of Medicine 310051, Hangzhou, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：